Jump to navigation
Enter the article’s url One of our curators will take care of it as soon as possible!
If peer review were a drug, it would never get on the market.
Editas, a company started by several gene-editing pioneers, gets new funding to develop treatments for blood cancers, eye diseases, and sickle-cell anemia.
Is public money being thrown away on scientific research whose results won’t hold up to scrutiny?
A deal being announced today with Genentech points the way for 23andMe to become a sustainable business.
It turns out that defining "raw" is a little trickier than it might seem.